Study of the Orsiro Drug Eluting Stent System
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 452 participants.
Also called NCT01356888
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 452 participants
- Sponsor
- Registry
-
NCT01356888
-
- Other papers using this trial's data
- Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial
- Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Austria, France, Germany, Hungary, Latvia, Netherlands, Spain, Switzerland
- Registry status
- Unknown status
Technical summary
Registry record NCT01356888. Randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2013-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Orsiro Drug Eluting Stent System
- Acronym
- BIOFLOW-II
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)
- Intervention (Device)
- Percutaneous Coronary Intervention (Orsiro DES)
- Lead sponsor
- Biotronik AG
Record details
- Record id
cardio:ct-nct01356888- Content hash
4ddb7d9632d938f2978e6ad33a08eb7fb3d535db3b33ff2b9163e010847aeef1